Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somebody selling $550 worth of stock does not constitute a seller. Further, if they were selling on this "insider info" that you claim only to make enough to buy a ham sandwich than they are a bigger moron than you.
So now that you have concluded that the stock has no future can you do us all a favour and go find another sandbox to play in?????
i was referenced in the back and forth "thread" today so a response was merely low hanging fruit. ..which you leave out there constantly. Just as a reminder this is a place where intelligent insight is supposed to meet with others that have something relevant to say about investment in GTHP....you provide none of that and therefore are just a big ball of THREAD. go elsewhere where you're verbal diarrhoea might be welcome.
you can prove only that he/she knows and takes the time to read filings by the company, that SURPRISE actually has meaningful material that a real investor would look for. You on the other hand, are just a huge YAWN. you bring nothing intelligent or insightful at all. spend more time trying to be a better human and leave the investing stuff to those that understand it.
10-Q today....foolish sellers in my opinion
In the United States, the Company is actively pursuing FDA approval by initiating a clinical trial protocol involving approximately 400 study participants, with the exact number depending in part on the numbers of women in the study both with and without cervical disease. The protocol was drafted with input from FDA and at least two prestigious clinical centers that are participating in the study.
Clinical study monitoring visits are required by FDA to ensure that the study is being conducted under FDA guidelines and in compliance with the study protocol. Findings from the initial clinical study monitoring visits include:
1)
There have not been any adverse events reported related to the use of LuViva.
2)
All three monitored clinical study sites are adhering to the study protocol and are completing the necessary case report forms according to FDA standards.
3)
Enrollment rates have increased during 2024.
4)
Approximately 122 patients have been enrolled and tested.
Based on current and expected enrollment rates, we expect the study to be completed in 2024, however there can be no assurance that the study will progress within the expected timeline.
a short position now of 26,500 now??? Thats a menacing notional value of $2600.00. WOW!!! I see a real short squeeze coming
Each of the 3 factual points you claim to have knowledge and understanding on is flat out WRONG!!! You really should check your facts before making such ridiculous comments as you are really just embarrassing yourself. Further, you must think you are the smartest guy in the room with your "Put your money where your mouth" challenge...give your head a shake man!!!!!
How about YOU...sell, sell and sell some more, then go away so that we can get some intelligent minds on this forum. you provide...at best, elementary knowledge of the capital markets and its not impressing anyone.
I'm just curious, do rainclouds follow you everywhere you go?? let me just fill you in on a little secret....for every share that somebody sells, there are buyers on the other side. those shares are not getting acquired in a shareholder buyback plan. so yes, there are buyers as well.
Lastly, Unless your DR walks on water...which I'm sure he/she doesn't, one must ask themselves, would such prestigious sites in the US agree to start a study if the technology was dated and inferior to that of the current standard of care???? NO THEY WOULDNT!!!!!! Also, would Dr. Kong Beihua of Qilu Hospital at Shandong University and Dr. Sui Long, Director of the Gynecology Hospital at Fudan University. Professor Kong is Vice Chairman of the Chinese Society of Obstetrics and Gynecology Society who are widely respected and in the top of their field get involved in a technology that, once again, is dated and inferior??? I THINK NOT.
You really should go back to the drawing board and do your homework this time before you come back and embarrass yourself again.
If your "mere opinion" came from a Dr...then it is not your mere opinion!!! Also not impressive that you know a Dr...i'm pretty sure everyone here knows 1 or 2 themselves. Ask yourself if your DR is a specialist in this field. Lastly...as a shareholder and supporter of the success of GTHP, may i kindly request that you redirect your uninformed/false verbal diarrhoea to another chat site that actually cares.
everyone has their reason for selling...a 2 year delay getting a USFDA study off the ground might be a good place to start. Using your primiitive valuation metrics, i suppose because some people were selling Citi Group once upon a time at $1 that represented fair value?????
i won't do your homework for you but just go and have a look at other cancer screening device companies and see where they were trading at the inflection points of 1. Starting the study. 2. completing and submitting the study. 3. approval. They are 12% in on the USFDA study and are very much lagging those that you would find in that comp group
smart money would share their opinion only when they have the position they are comfortable with. As for you, if you haven't spent your allowance money for the week maybe you should add 100 more shares
Latest 10-Q.......
USFDA study... 12% of the total number of patients needed for the study have been enrolled and tested.
Chinese NMPA.... As of October 31st there are 12 patients left to complete the study
Pretty sure that warrants a market cap far greater than where we are at
According to my Bloomberg, Auctus had 365,800 shares prior to the last financing last September which were sold in January and beginning of February of this year....according to their last filing March 23, 2023. So it looks like all they have left is what they have from that last financing...all of which is underwater. That said, i agree that they are probably not likely to be a seller of GTHP in the face of a SEC investigation.
This is clearly someone with liquidity issues...who the hell would sell a cancer screening device company that has just started a SMALL follow on study for FDA approval at current levels. Makes no sense!!!
VERY ENCOURAGING!!!!!! I hope the market gets that this money takes them to completion of the FDA study...which is a huge milestone and historically for screening devices is a significant creator of shareholder value.
Also, i have read a lot of posts busting managements chops for delays with FDA study...last i heard there was a thing called COVID that created huge bottlenecks in the entire medical system...even Elon Musk with all the money in the world has had 3 years of delays starting with FDA for Neurolink.